122 related articles for article (PubMed ID: 7513437)
21. Endocrine therapy for benign prostatic hyperplasia in the 90's.
Ekman P
J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial.
Yu HJ; Chiu TY; Lai MK
J Formos Med Assoc; 1995; 94(1-2):37-41. PubMed ID: 7542109
[TBL] [Abstract][Full Text] [Related]
23. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
[TBL] [Abstract][Full Text] [Related]
24. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
Tkachuk VN; Al'-Shukri SKh; Kornienko VI; Kuz'min IV
Urol Nefrol (Mosk); 1998; (4):37-9. PubMed ID: 9727320
[TBL] [Abstract][Full Text] [Related]
25. Early diagnosis of prostate cancer in finasteride treated BPH patients.
Tarle M; Kraus O; Trnski D; Reljic A; Ruzic B; Katusic J; Spajic B; Kusic Z
Anticancer Res; 2003; 23(1B):693-6. PubMed ID: 12680169
[TBL] [Abstract][Full Text] [Related]
26. Clinical and biological characteristics of familial benign prostatic hyperplasia.
Sanda MG; Doehring CB; Binkowitz B; Beaty TH; Partin AW; Hale E; Stoner E; Walsh PC
J Urol; 1997 Mar; 157(3):876-9. PubMed ID: 9072590
[TBL] [Abstract][Full Text] [Related]
27. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Kaplan SA; McConnell JD; Roehrborn CG; Meehan AG; Lee MW; Noble WR; Kusek JW; Nyberg LM;
J Urol; 2006 Jan; 175(1):217-20; discussion 220-1. PubMed ID: 16406915
[TBL] [Abstract][Full Text] [Related]
29. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
Marberger MJ
Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
[TBL] [Abstract][Full Text] [Related]
30. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group.
Andersen JT; Ekman P; Wolf H; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
Urology; 1995 Nov; 46(5):631-7. PubMed ID: 7495111
[TBL] [Abstract][Full Text] [Related]
31. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial.
Guess HA; Heyse JF; Gormley GJ; Stoner E; Oesterling JE
Urol Clin North Am; 1993 Nov; 20(4):627-36. PubMed ID: 7505970
[TBL] [Abstract][Full Text] [Related]
32. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
Marks LS; Partin AW; Gormley GJ; Dorey FJ; Shery ED; Garris JB; Subong EN; Stoner E; deKernion JB
J Urol; 1997 Jun; 157(6):2171-8. PubMed ID: 9146609
[TBL] [Abstract][Full Text] [Related]
33. The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia.
Nacey JN; Meffan PJ; Delahunt B
Aust N Z J Surg; 1995 Jan; 65(1):35-9. PubMed ID: 7529489
[TBL] [Abstract][Full Text] [Related]
34. Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies. The Finasteride Study Group.
Grino P; Stoner E
Eur Urol; 1994; 25 Suppl 1():24-8. PubMed ID: 7507052
[TBL] [Abstract][Full Text] [Related]
35. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group.
Prostate; 1993; 22(4):291-9. PubMed ID: 7684524
[TBL] [Abstract][Full Text] [Related]
36. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia.
Stoner E
Urology; 1994 Mar; 43(3):284-92; discussion 292-4. PubMed ID: 7510911
[TBL] [Abstract][Full Text] [Related]
37. Treating benign prostatic hyperplasia with finasteride in Chinese men: one-year experience.
Chueh SC; Yu HJ; Chiu TY; Huang CY; Lai MK
J Formos Med Assoc; 1996 Aug; 95(8):650-2. PubMed ID: 8870441
[TBL] [Abstract][Full Text] [Related]
38. Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation.
Kirby RS; Bryan J; Eardley I; Christmas TJ; Liu S; Holmes SA; Vale JA; Shanmuganathan K; Webb JA
Br J Urol; 1992 Jul; 70(1):65-72. PubMed ID: 1379107
[TBL] [Abstract][Full Text] [Related]
39. [Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study.].
Einarsson GV; Andersen JT; Gislason T; Wolf H; Ekman P; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
Laeknabladid; 1996 Dec; 82(12):859-66. PubMed ID: 20065399
[TBL] [Abstract][Full Text] [Related]
40. A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia.
Ekman P
Drug Saf; 1998 Mar; 18(3):161-70. PubMed ID: 9530536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
